Nam Atiqur Rahman

8PUBLICATIONS
101CO-AUTHORS
Gene and molecular therapyMedical biotechnology not elsewhere classifiedMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Flight dynamics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 05, 2025
FDA Approval Summary: Vorasidenib for IDH-Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery.

Michael I Barbato, Amy K Barone, Stephanie L Aungst

|Aug 18, 2025
FDA Approval Summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-Unresponsive Carcinoma In Situ.

Brian L Heiss, Elaine Chang, Hee-Koung Joeng

|Jan 14, 2025
FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma.

Sonia Singh, Diana Bradford, Somak Chatterjee

|Sep 04, 2024
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma.

Michael H Brave, William F Maguire, Chana Weinstock

|Jul 29, 2024
Dosage Optimization: A Regulatory Perspective for Developing Oncology Drugs.

Atiqur Rahman, Mirat Shah, Stacy S Shord

|Jun 14, 2024
FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer.

Michael I Barbato, Diana Bradford, Yi Ren

Pageof 2

Frequent Collaborators

7 joint publications

Richard Pazdur

6 joint publications

Paul G Kluetz

6 joint publications

Shenghui Tang

4 joint publications

Youwei Bi